Wealthfront Advisers LLC Alnylam Pharmaceuticals, Inc. Transaction History
Wealthfront Advisers LLC
- $29.7 Billion
- Q2 2024
A detailed history of Wealthfront Advisers LLC transactions in Alnylam Pharmaceuticals, Inc. stock. As of the latest transaction made, Wealthfront Advisers LLC holds 8,096 shares of ALNY stock, worth $2.2 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
8,096
Previous 8,090
0.07%
Holding current value
$2.2 Million
Previous $1.21 Million
62.7%
% of portfolio
0.01%
Previous 0.0%
Shares
11 transactions
Others Institutions Holding ALNY
# of Institutions
639Shares Held
108MCall Options Held
2.11MPut Options Held
2.04M-
Capital World Investors Los Angeles, CA15MShares$4.08 Billion0.61% of portfolio
-
Vanguard Group Inc Valley Forge, PA12.5MShares$3.4 Billion0.06% of portfolio
-
Black Rock Inc. New York, NY9.55MShares$2.6 Billion0.05% of portfolio
-
Wellington Management Group LLP Boston, MA6.21MShares$1.69 Billion0.28% of portfolio
-
Baillie Gifford & CO4.89MShares$1.33 Billion1.03% of portfolio
About ALNYLAM PHARMACEUTICALS, INC.
- Ticker ALNY
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 123,028,000
- Market Cap $33.5B
- Description
- Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...